Sub menu

 
 

PPD Australia Pty Ltd

Regulatory activities for this sponsor.

Type

Date

7 result(s) found, displaying 1 to 7

  • AusPAR: Erwinase

    Australian Public Assessment Report (AusPAR)
    Erwinase (crisantaspase) has been approved for the treatment of acute lymphoblastic leukemia (ALL) as a component of a multi-agent chemotherapeutic regimen for patients who have developed hypersensitivity to pegylated asparaginase.

  • Erwinase (crisantaspase)

    Prescription medicine decision summary
    Erwinase (crisantaspase) has been approved as a component of a multi-agent chemotherapeutic regimen for the treatment of patients with acute lymphoblastic leukemia who have developed hypersensitivity to pegylated asparaginase obtained from E. coli.

  • AusPAR: Nuceiva

    Australian Public Assessment Report (AusPAR)
    Nuceiva (prabotulinum toxin A) is indicated for the temporary improvement in appearance of glabellar lines.

  • Nuceiva

    Prescription medicine decision summary
    Nuceiva (prabotulinumtoxinA) is approved to treat glabellar lines.

Help us improve the Therapeutic Goods Administration site